Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis

Sung-Hee Kim\textsuperscript{a}, Sarah M. Gerver\textsuperscript{b}, Sarah Fidler\textsuperscript{c} and Helen Ward\textsuperscript{b}

Objective: Adolescent and young adult (AYA) populations (12–24 years) represent over 40% of new HIV infections globally. Adolescence is sometimes characterized by high-risk sexual behaviour and a lack of engagement with healthcare services that can affect adherence to antiretroviral therapy (ART). Despite adherence to ART being critical in controlling viral replication, maintaining health and reducing onward viral transmission, there are limited data on ART adherence amongst AYA globally. We undertook a systematic review and meta-analysis of published studies reporting adherence to ART for AYA living with HIV.

Design and methods: Searches included Embase, Medline and PsychINFO databases up to 14 August 2013. Eligible studies defined adequate adherence as at least 85% on self-report or undetectable blood plasma virus levels. A random effects meta-analysis was performed and heterogeneity examined using meta-regression.

Results: We identified 50 eligible articles reporting data from 53 countries and 10 725 patients. Using a pooled analysis of all eligible studies, 62.3% [95% confidence interval (CI) 57.1–67.6; \(I^2\) : 97.2%] of the AYA population were adherent to therapy. The lowest average ART adherence was in North America [53% (95% CI 46–59; \(I^2\) : 91%)], Europe [62% (95% CI 51–73; \(I^2\) : 97%)] and South America [63% (95% CI 47–77; \(I^2\) : 85%] and, with higher levels in Africa [84% (95% CI 79–89; \(I^2\) : 93%)] and Asia [84% (95% CI 77–91; \(I^2\) : 0%].

Conclusion: Review of published literature from Africa and Asia indicate more than 70% of HIV-positive AYA populations receiving ART are adherent to therapy and lower rates of adherence were shown in Europe and North America at 50–60%. The global discrepancy is probably multifactorial reflecting differences between focused and generalised epidemics, access to healthcare and funding.

Keywords: adolescence, antiretroviral therapy, highly active, HIV, medication adherence, patient compliance, young adult

Introduction

Into the third decade of the HIV/AIDS epidemic, there are 34 million people living with HIV in the world, of whom five million are aged between 15 and 24 years [1]. Adolescence is a period of mental, physical and emotional maturation wherein commonly individuals undergo behavioural experimentation, identity formation, risk taking and face difficult choices on romantic relationships, sexual behaviour and alcohol and recreational drug use [2,3]. Furthermore, young people often have poorly developed life skills and are often lacking in worldly knowledge and financial autonomy [4]. They also have limited access to health facilities and are prone to sexual coercion and peer pressure [4]. Adolescents have been described as the ‘fulcrum’ and the ‘centre of the epidemic’ [5], with 42% of new HIV infections occurring in this age group in 2010 [1]. For all of these reasons, adolescents have been frequently recognized as a vulnerable group to becoming infected
and to being marginalized from mainstream healthcare provisions [6].

Despite the dramatic improvement in survival and marked reduction in transmission through antiretroviral therapy (ART), a sustained effect depends on high levels of adherence (>95%) to daily oral dosing [7,8]. Poor ART adherence increases the risk of viral drug-resistance, limits treatment efficacy, leading to disease progression, and reduces future therapeutic options [9] as well as increasing the risk of transmission due to unsuppressed viral replication [10].

Following the publication of the HPTN052 study [10] and the accompanying paradigm shift in HIV prevention approaches to using ART strategically for all people living with HIV to significantly reduce the risk of onward viral transmission, successful viral suppression amongst core risk-taking groups, which include Adolescent and young adult (AYA) living with HIV, has a renewed focus. Mathematical models have explored the potential elimination of HIV transmission with a universal HIV testing approach accompanied by immediate ART for all HIV-positive individuals, but this must include AYA if it is to confer a population-level effect. The few studies on adherence show that access to antiretroviral and adherence is lower in adolescents than in the adult population [11–16]. There has been one previous review of ART adherence among HIV-infected youth [2], which showed adherence rates ranging from 28.3 to 69.8% in the USA. This review aims to update the findings of the previous review and quantifying adherence in AYA at a global level.

Materials and methods

Search strategy and selection criteria

We followed the PRISMA guidelines in carrying out this research [17]. Articles were identified through searches conducted on Medline, Embase, HMIC, Maternity and Infant Care, and PsychINFO up to 14 August 2013 using combinations of keywords such as ‘adolescent’, ‘young adult’, ‘adherence’, ‘patient compliance’, ‘antiretroviral therapy’ and ‘antiretrovirals’ as MESH headings and free-text terms. Bibliographies of potentially eligible full-text publications were also searched and when necessary, authors of relevant studies were contacted for clarification and for additional information. Potentially eligible studies were downloaded into EndNote, and titles and abstracts were searched according to the predefined inclusion and exclusion criteria.

We included quantitative studies reporting original data on medication adherence among HIV-infected youth (ages 12–24 years). Studies that included participants outside this age range were included where the median age of participants fell within the 12–24 year range. Studies were included if adherence was measured by subjective measurement (self-reported adherence), pharmacologic measurements (pill count, pharmacy refill records) or physiological methods (viral suppression). Despite being a subjective measure, self-report is non-invasive, easy to administer and has been shown to correlate with objective measures such as pill counts [18,19]. Although viral load is an indirect measure, many studies have indicated that high adherence (>95%) is needed to maintain adequate virologic suppression [20–22].

Studies were included if they defined adherence as 100%, more than 95%, more than 90% and more than 85% of the medication taken correctly for a defined period in the study, or viral suppression as the lower limit detectable at the time and location defined by the authors (range <50 to <500 copies/ml). The studies also had to show the proportion of their population that was adequately adherent according to the study definition rather than reporting mean adherence. All study designs were included except for guidelines, reviews and case studies. The length of follow-up was left undefined and the studies were only considered if published after 1996 (the designated start of highly active ART era). Only English publications were included. Finally, studies were excluded if the population was deemed unrepresentative of the general adolescent population living with HIV (e.g. containing experimental interventions to promote adherence, financial incentives).

Study selection and data extraction

Two investigators (S.K., S.M.G.) conducted the search, reviewed all abstracts and full-text articles independently, with final inclusion decided through consensus with verification with senior study authors when needed. We extracted the data independently and in duplicate. The country, study year, sample size, age, sex, methods of adherence measurement and outcomes were extracted from each study. When more than one adherence measurement was used, data on all measures were extracted and the most objective method was chosen for the analysis (e.g. viral suppression). When a study examined the effect of an intervention on medication adherence, only the adherence data for the control group were extracted and analysed. Information on disease state, type of antiretroviral regimen, the time the individuals were on treatment for and socio-economic status were not abstracted due to large heterogeneity of each study population. For all studies, ART was taken as potent standard triple therapy.

Data analysis

Point estimates and Clopper–Pearson confidence intervals (CIs) [23] were calculated and the transformed data were pooled using DerSimonian–Laird [24] random effects model, as large heterogeneity was anticipated considering the varied populations, healthcare systems and the nature of the epidemic. We explored potential sources of heterogeneity with univariate, random-effects
meta-regression using continents, measures of adherence, thresholds of adherence, percentage of women in the study, study year (pre-2005 and 2005 onwards) and age of participants (< 20 vs. ≥ 20 years) as variables because they were identified as potential factors that might explain the heterogeneity observed in the analysis. We did analyses using Stata version 11 [25].

Forest plots were created for each region that showed individual study proportions meeting the threshold for appropriate adherence (as defined by the original study) with Clopper–Pearson CIs, the overall DerSimonian–Laird pooled estimate and the $I^2$-value for heterogeneity. Results are reported as combined adherence proportions with 95% CIs.

Results

Fifty-one studies published between 1999 and 2013 passed the full-text screening and reported adherence rates for 10,725 patients in 53 countries. Seven studies were reported in national or international conference abstracts [26–30]; the rest as full-text articles. A flow diagram of studies included in the analysis is detailed in Fig. 1, with characteristics displayed in Table 1 [31–73] grouped by geographical region. Studies reported similar thresholds for adherence monitoring (e.g. 100%, >95%, ≥90%, ≥85%) and viral suppression was most commonly defined as less than 400 copies/ml. Pooled adherence rates across all studies are summarized in Table 2 with forest plots by region in Fig. 2. Adherence was estimated at 62% (95% CI, 57–68; $I^2$, 97%) overall and this varied by region as summarized in the Table 2; it was lowest in North America (53%) and highest in Africa and Asia (84%). There was considerable heterogeneity between studies as shown by large $I^2$ values. We used meta-regression to examine the impact of continent, adherence measure, adherence threshold (100%, ≥95%, ≥90%, ≥85%), sex (<50% or ≥50% women), age group (<20 or ≥20 years old) and study year (before 2005 or after/including 2005) on this heterogeneity (Table 3); however, none of the variables fully explained the between-study heterogeneity.

Studies conducted after 2005 showed higher adherence rate (74%) than conducted pre-2005 (59%). The majority (98%) of the studies used either viral suppression (n = 36) or self-report (n = 13) as the adherence measure. Other measurements included pharmacy refills. Nine American studies measured adherence by self-report, but only two South American, one Asian study and one African study measured using self-report. On the contrary, viral suppression was a more common form of measurement outside North America, with 13 of 22 studies in North America, all 12 in Europe, three of five in South America, six of eight in Africa and two of three in Asia. Nine studies had multiple measures.

In order to assess whether the measure of adherence used by the different studies had an impact on the prevalence of adolescent adherence, we ran additional and separate meta-analyses for those studies that had viral suppression
Table 1. Characteristics of studies included by global region.

| Source                  | Study year | No of participants | Female % | Race/Ethnicity % | Age (years) | Assessment of adherence | Adherence, % threshold for measurement | No adherence (%) |
|-------------------------|------------|--------------------|----------|------------------|-------------|--------------------------|----------------------------------------|-----------------|
| North America (n=22 studies) |            |                    |          |                  |             |                          |                                        |                 |
| Belzer et al [34]       | 1997–1998  | 31                 | 36       | Hispanic         | 42          | 13–24 Patient           | 90; doses in the past 3 months         | 19 (61)         |
| Buchanan et al [35]     | 2000–2007  | 120                | 46       | Black            | 39          | 8–18 VL                  | <400 copies/ml                           | 72 (60)         |
| Calabrese et al [16]    | 2003–2005  | 25                 | 48       | Hispanic         | 28          | Median: 12.8             | 100; based on past 1 month              | 54 (45)         |
| Chandwani et al [37]    | 2003–2005  | 107                | 54       | Black            | 69          | 13–21 Patient           | <400 copies/ml                           | 72 (60)         |
| Charles et al [14]      | 2003–2005  | 79                 | 66       | Hispanic         | 24          | Mean: 16.4               | 100; based on past 3 days               | 54 (45)         |
| Comulada et al [38]     | 1999–2000  | 136                | 29       | Hispanic         | 60          | 14–29 Patient           | <50 copies/ml                            | 39 (49)         |
| Flynn et al [39]        | 1999–2001  | 118                | 51       | Black            | 47          | 8–22 VL                  | <400 copies/ml                           | 69 (59)         |
| Garvie et al [40]       |            | 57                 | 47       | Hispanic         | 90          | 16–23 VL                | 100; based on past 3 days               | 47 of 60 (78)   |
| Hessik et al [41]       |            | 42                 | 41       | Black            | 66          | Mean: 19.9               | 95; doses taken in past 2 weeks         | 18 (43)         |
| Mathulika et al [42]    |            | 144                | 48       | Hispanic         | 12          | 9–16 Mean: 13.9          | 100; based on past month                | 62 (43)         |
| Martin et al [43]       |            | 24                 | 46       | Black            | 46          | Mean: 13.9               | MEMS                                    | 5 (21)          |
| Martinez et al [44]     | 2003–2005  | 60                 | 100      | Black            | 73          | 15–24 Patient           | <50 copies/ml                            | 39 (45)         |
| Mellins et al [45]      | 2007–10    | 238                | 50       | Hispanic         | 21          | Mean: 20.6               | 100; based on past 4 days               | 39 (65)         |
| Murphy et al [12]       | 1998–99    | 231                | 73       | Black            | 73          | Mean: 13.7               | 100; based on past 7 days               | 131 (59)        |
| Murphy et al [46]       | 2003–2005  | 136                | 66       | Black            | 50          | Mean: 16.4               | 100; based on past 2 weeks              | 8 (44)          |
| Park and Nachman [47]   | 2003–2005  | 136                | 55       | Black            | 60          | Mean: 13.7               | 100; based on past 7 days               | 54 (38)         |
| Rudy et al [48]         | 2003–2005  | 136                | 55       | Black            | 60          | Mean: 15.7               | 12–24 Patient                           | 274 (75)        |
| Rudy et al [49]         | 2003–2005  | 136                | 55       | Black            | 60          | Mean: 15.7               | 12–24 Patient                           | 274 (75)        |
| Ryscavage et al [16]    | 2003–2005  | 136                | 55       | Black            | 60          | Mean: 15.7               | 12–24 Patient                           | 274 (75)        |
| Van Der Linden et al [50] | 2003–2005 | 136                | 55       | Black            | 60          | Mean: 15.7               | 12–24 Patient                           | 274 (75)        |
| Source                        | Study year | Country         | No of participants | Female % | Age (years) | Assessor | Adherence, % | threshold for measurement | No adherence (%) |
|------------------------------|------------|-----------------|--------------------|----------|-------------|----------|--------------|--------------------------|-----------------|
| **African studies (n = 8)**  |            |                 |                    |          |             |          |              |                          |                 |
| Bakeera-Kitaka et al. [51]   | 2004–2006  | Uganda          | 118                | 64       | 10–19       | VL       | <400 copies/ml | 93 (79)                  |                 |
| Evans et al. [33]            | 2004–2010  | S. Africa       | 1206               | 81       | 10–24       | VL       | <400 copies/ml | 1054 (87)               |                 |
| Mutuvedzi et al. [31]        | 2004–2010  | S. Africa       | 808                | 87       | 16–24       | VL       | <400 copies/ml | 660 (82)                 |                 |
| Nabiharee-Barungi et al. [54]| 2004–2005  | Uganda          | 60                 | 67       | 12–18       | Pill count | Unannounced  | 95 (72)                  |                 |
| Nachega et al. [55]          | 1999–2006  | Southern Africa | 92                 | 73       | 11–19       | Pharmacy refill | 900 (81) | 17 of 82 (21) |                         |                 |
| **Asian studies (n = 3)**    |            |                 |                    |          |             |          |              |                          |                 |
| Lee et al. [58]              | 1997–2010  | Taiwan          | 7                  | 10       | 16–20       | VL       | <400 copies/ml | 5 (71)                   |                 |
| Narkbunnam et al. [59]       | 2010       | Thailand        | 71                 | 51       | 12–18       | VL       | <400 copies/ml | 69 (85)                  |                 |
| Rongkavilit et al. [13]      | 2004       | Thailand        | 28                 | 59       | 16–25       | Mean: 14.7 | Patient      | 95 (82)                  |                 |
| **European studies (n = 12)**|            |                 |                    |          |             |          |              |                          |                 |
| Avettand-Fenoel et al. [60]  | 2007–2009  | France          | 79                 | 57       | 15–24       | VL       | <500 copies/ml | 59 (75)                  |                 |
| Cairns et al. [61]           | 2012       | UK              | 117                | 56       | 12          | VL       | <500 copies/ml | 133 (97)                 |                 |
| De Milder et al. [62]        | 1997–2011  | Spain           | 243                | 56       | 18–24       | VL       | <400 copies/ml | 128 (56)                 |                 |
| Dima et al. [63]             | 2011–2012  | Romania         | 162                | 53       | 57          | Pill count | 95 (72)     | 91 (56)                  |                 |
| Elgalib et al. [28]          | 2000–2007  | UK              | 17                 | 49       | 10–17       | VL       | <500 copies/ml | 97 (60)                  |                 |
| Ellis et al. [65]            | 2005–2009  | UK              | 58                 | 100      | 13–19       | VL       | <400 copies/ml | 87 (51)                  |                 |
| Foster et al. [66]           | 1996–2007  | UK&Ireland      | 396                | 64       | 12–17       | VL       | <500 copies/ml | 32 (55)                  |                 |
| Function et al. [67]         | 1999–2003  | France          | 29                 | 63       | 5–18        | Mean: 14.2 | Patient      | 95 (73)                  |                 |
| Kline et al. [68]            | 2001–06    | Romania         | 265                | 46       | 13–17       | Mean: 16.5 | Patient      | 92 (86)                  |                 |
| Sabih et al. [32]            | 1998–06    | Rome            | 338                | 63       | 13–17       | VI       | <500 copies/ml | 92 (46)                  |                 |
| **South American studies (n = 5)** |            |                 |                    |          |             |          |              |                          |                 |
| de Matos et al. [70]         | 2002–2009  | Brazil          | 9                  | 100      | 13–19       | VL       | <80 copies/ml  | 6 (67)                   |                 |
| Filho et al. [71]            | 1993–2009  | Brazil          | 101                | 54       | 10–19       | Patient   | 95 (72)     | 10 (33)                  |                 |
| Santarem Emesto et al. [27]  | 2008–2009  | Brazil          | 108                | 44       | 7–19        | Patient   | 95 (72)     | 10 (33)                  |                 |
| Souza et al. [73]            | 2006–2007  | Brazil          | 49                 | 74       | Mean 13.2   | VI       | <400 copies/ml | 26 (53)                  |                 |

MEMS, Medication Event Monitoring System; VL, viral load.

*a* Haiti.

*b* Canada.

*c* Further details were verified through personal correspondence with the author.
Table 2. Percentage adherence by subgroups.

| Number of studies | % adherence | 95% CI |
|-------------------|-------------|--------|
| Overall            | 50          | 62.3   | 57.1–67.6 |
| North America      | 22          | 52.7   | 46.3–59.0 |
| Africa             | 8           | 81.8   | 78.9–84.7 |
| Asia               | 3           | 83.9   | 76.8–91.0 |
| Europe             | 12          | 62.0   | 50.7–73.3 |
| South America      | 5           | 62.8   | 46.6–77.0 |
| Sex                |             |        |          |
| ≥50% female        | 27          | 65.6   | 58.8–72.4 |
| <50% female        | 15          | 54.3   | 45.9–62.7 |
| Age                |             |        |          |
| Adolescents [12–29] | 34          | 60.1   | 53.1–67.0 |
| Young adults [20–24]| 10          | 67.9   | 58.6–77.3 |
| Study year         |             |        |          |
| Before 2005        | 22          | 59.3   | 49.2–69.4 |
| 2005 onwards       | 16          | 77.0   | 72.0–82.0 |
| Adherence measure  |             |        |          |
| Viral load         | 36          | 62.2   | 56.0–68.4 |
| Self-report        | 20          | 59.1   | 51.8–66.4 |

CI, confidence interval. If viral load (VL) is taken as the primary measure, adherence is as follows: VL 62% (95% CI 56–68), self-report 62% (95% CI 51–71) and pill count 72% (95% CI 60–84).

*Publications with multiple measures were included in this subgroup analysis.

Discussion

The findings from this systematic review and meta-analysis showed that overall, from studies globally, 62% of adolescents and young adults were adherent to ART (as defined by >85%, 90%, 95%, 100%) during the time defined by the study or through viral suppression. There were differences between regions with lower adherence in Europe, South America and North America and higher levels in Africa and Asia. There are no other global estimates of adherence in this group, although a meta-analysis of North American studies by Reissner and Mimiaga [2] reported rates between 28.3 and 69.8%. We have updated these figures by adding 13 additional studies in North America that were published after this review, which showed similarly disparate results (28.0–74.5%). Geographic variation in adherence has also been reported for adults. Mills et al. [74] carried out a meta-analysis of adult adherence to ART and found similar estimates both overall [64% (95% CI, 59–70); F, 99%] and by region: they estimated adherence at 55% (95% CI, 49–62) amongst adults in North America and 77% (95% CI, 68–85) in Africa, similar to our findings of 53 and 84%, respectively. They did not include studies from other regions.

In contrast, our results suggest lower adherence in adolescents than adults for Europe; a multicentre prospective cohort study in 17 European countries with 1323 adult patients [75] showed 80% of its population achieving virological suppression (95% CI, 78–82), significantly higher than our adolescent estimate of 62% (95% CI, 51–73). Similarly, a Brazilian study with 1972 adult patients [76] with 75% of the study population achieving more than 95% adherence (95% CI, 73–77) is also higher than the adolescent population estimate for South America of 63% (95% CI, 47–77). There are fewer studies in Asian adults or adolescents: a study of 149 Thai adults showed 77% adherence (95% CI, 71–84) [77], comparable to the 83% (95% CI, 77–89) we found in adolescents.

Thus, in comparison with the adult levels, we have found lower adherence in adolescents in Europe and South America, while in North America and Africa and possibly Asia levels are comparable to adults. This is unanticipated given that many studies comparing viral suppression between adolescents and adults showed that adolescents are less likely to achieve viral suppression than the adult population [31,33,78,79]. Possible reasons could be either a selection from African, North American and Asian studies, as individuals enrolled in a study are more likely to be those who are more engaged in care, or a real difference due to variation in the meaning and experience of adolescence in different settings. It may be that in Africa and Asia, the population enrolled in the study have little differences than the adult population in the same setting culturally and socially, especially when they are a bit older (16–24 years). They are likely to have already worked and may have children of their own, compared with the adolescent population in Europe and South America where there are bigger differences in the adult and adolescent age groups.

The regional disparity in adherence, now documented in adolescents and adults, may reflect the significant differences in the healthcare systems between North America and Africa [5,80] and the different HIV epidemic, with Africa having a generalized epidemic in comparison with a focused epidemic in North America and Europe [5,81]. This observation is most likely multifactorial, but probably reflects the communities most affected by HIV as well as the different funding and accessibility of the healthcare services. For instance, in resource-poor regions with generalized epidemics, HIV testing and ART provision are widespread and can include house to house testing and care. In addition, it is usually free for eligible individuals [82] whilst in North America and Europe the HIV epidemic remains focused often being ‘hidden’ amongst certain vulnerable, core risk groups with less access to healthcare despite disproportionately richer resources [6]. The latest figures from North America show a high prevalence and incidence rates amongst MSM AYA of African and Hispanic descent [83], a group typically marginalized outside of healthcare.

Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
provision with high rates of incarceration, which is also linked with poor ART adherence [84]. In the UK, a disproportionate number of ‘late presenters’ to healthcare come from Black African communities [85]. Furthermore, in sub-Saharan Africa where HIV incidence and prevalence globally is highest, AYA women are likely to become pregnant in the second decade of life [86]. In order to achieve the IAS goals of an HIV-free

### Meta-analysis adherence to antiretroviral therapy in adolescents Kim et al.

#### (a) North America

| Author                | Prevalence (95% CI) | %    |
|-----------------------|---------------------|------|
| Belzer et al, 1999   | 61.29 (42.19, 78.15) | 3.77 |
| Buchanan et al, 2012 | 60.00 (50.66, 68.83) | 4.90 |
| Calabrese et al, 2012| 28.00 (12.07, 49.39) | 3.69 |
| Chandwani et al, 2012| 28.04 (19.78, 37.55) | 4.93 |
| Charif et al, 2008   | 49.37 (37.92, 60.86) | 4.62 |
| Comulada et al, 2003 | 62.50 (53.79, 70.65) | 4.97 |
| Flynn et al, 2004    | 58.47 (49.04, 67.47) | 4.89 |
| Garvie et al, 2010   | 68.42 (54.76, 80.09) | 4.47 |
| Hosek et al, 2005    | 42.86 (27.72, 59.04) | 4.08 |
| Marhefka et al, 2010 | 43.06 (34.84, 51.56) | 4.98 |
| Martin et al, 2007   | 37.50 (18.80, 59.41) | 3.48 |
| Martinez et al, 2012 | 65.00 (51.60, 76.87) | 4.47 |
| Mellins et al, 2011  | 64.29 (57.84, 70.37) | 5.18 |
| Murphy et al, 2001   | 68.40 (61.98, 74.34) | 5.19 |
| Murphy et al, 2010   | 33.66 (24.56, 43.75) | 4.85 |
| Park and Nachman, 2010| 61.11 (35.75, 82.70) | 3.10 |
| Rudy et al, 2010     | 74.46 (69.68, 78.84) | 5.31 |
| Rudy et al, 2009     | 62.63 (57.65, 67.41) | 5.29 |
| Ryscavage et al, 2011| 58.70 (43.23, 73.00) | 4.18 |
| Van Der Linden et al, 2011| 44.44 (30.92, 58.60)| 4.32 |
| Wiens et al, 2004    | 32.35 (17.39, 50.53) | 3.96 |
| Williams et al, 2006 | 43.52 (39.99, 47.10) | 5.37 |
| Overall (I-squared = 91.4%, P = 0.000) | 52.74 (46.46, 59.03) | 100.00 |

**NOTE:** Weights are from random effects analysis

![Fig. 2.](image) **Prevalence of adherence**

#### (b) Africa

| Author                      | Prevalence (95% CI) | %    |
|-----------------------------|---------------------|------|
| Bakeera-Kitaka et al, 2008  | 78.81 (70.33, 85.80) | 11.80 |
| Evans et al, 2013           | 67.40 (65.39, 69.22) | 16.20 |
| Mutevedzi et al, 2011       | 81.68 (78.84, 84.29) | 15.80 |
| Nabukeera-Barungi et al, 2007| 71.67 (58.56, 82.55) | 8.38 |
| Nachega et al, 2009         | 63.04 (52.34, 72.88) | 9.66 |
| Nglazi et al, 2012          | 90.07 (87.35, 92.37) | 15.92 |
| Van Cutsem et al, 2010      | 94.76 (92.41, 96.55) | 16.13 |
| Wiens et al, 2012           | 93.33 (90.58, 96.83) | 6.10 |
| Overall (I-squared = 93.0%, P = 0.000) | 83.78 (78.85, 88.72) | 100.00 |

**NOTE:** Weights are from random effects analysis

![Fig. 2.](image) **Prevalence of adherence**
### (c) Asia

| Author                  | Prevalence (95% CI) | Weight |
|-------------------------|---------------------|--------|
| Lee et al, 2012         | 71.43 (20.04, 96.33) | 4.49   |
| Narkbunnam et al, 2012  | 85.19 (75.55, 92.10) | 74.14  |
| Rongkavilit et al, 2007 | 82.14 (63.11, 93.94) | 21.37  |
| Overall (I-squared = 0.0%, \(P = 0.715\)) | 83.92 (76.79, 91.04) | 100.00 |

NOTE: Weights are from random effects analysis

### (d) Europe

| Author                  | Prevalence (95% CI) | Weight |
|-------------------------|---------------------|--------|
| Avettand-Fenoel et al, 2012 | 74.68 (63.64, 83.80) | 8.53  |
| Cairns et al, 2013      | 96.58 (91.48, 99.06) | 9.06   |
| de Mulder et al, 2012   | 55.90 (49.21, 62.43) | 8.87   |
| Dima et al, 2013        | 56.17 (48.17, 63.95) | 8.76   |
| Dolflus et al, 2010     | 50.58 (42.87, 58.28) | 8.78   |
| Eisen et al, 2009       | 47.06 (22.98, 72.19) | 6.38   |
| Elgalib et al, 2009     | 55.17 (41.54, 68.26) | 8.11   |
| Ellis et al, 2012       | 64.29 (44.07, 81.36) | 7.33   |
| Foster et al, 2009      | 78.03 (73.62, 82.01) | 9.04   |
| Funck-Brentano et al, 2005 | 37.93 (20.69, 57.74) | 7.35   |
| Kline et al, 2007       | 72.45 (66.65, 77.74) | 8.95   |
| Sabin CA et al, 2008    | 45.77 (38.74, 52.93) | 8.83   |
| Overall (I-squared = 96.5%, \(P = 0.000\)) | 62.00 (50.70, 73.31) | 100.00 |

NOTE: Weights are from random effects analysis

### (e) South America

| Author                  | Prevalence (95% CI) | Weight |
|-------------------------|---------------------|--------|
| Cruz et al, 2010        | 66.67 (29.93, 92.51) | 12.34  |
| de Matos et al, 2012    | 33.33 (17.29, 52.81) | 19.10  |
| Filho et al, 2008       | 79.21 (69.99, 86.64) | 23.98  |
| Santerem Ernesto et al, 2012 | 72.22 (62.78, 80.41) | 23.75  |
| Souza et al, 2010       | 53.08 (38.27, 67.47) | 20.86  |
| Overall (I-squared = 84.8%, \(P = 0.000\)) | 61.79 (46.57, 77.01) | 100.00 |

NOTE: Weights are from random effects analysis

Fig. 2. (Continued): (c) Asia, (d) Europe, and (e) South America.
Table 3. Odds ratios from meta-regression results of all studies (n = 50).

| Category                      | Univariate analysis |   |
|-------------------------------|---------------------|---|
|                               | OR (95% CI)         | P  |
| No covariate                  |                     |   |
| Sex                           |                     |   |
| ≥50% female                   | 27                  | 1  |
| <50% female                   | 15                  | 0.6 (0.4–1.1) | 0.13 |
| Continent                     |                     |   |
| North America                 | 22                  | 1  |
| Africa                        | 8                   | 2.1 (1.1–5.0) | 0.04 |
| Asia                          | 3                   | 0.8 (0.3–2.8) | 0.78 |
| Europe                        | 12                  | 1.7 (0.9–3.3) | 0.11 |
| South America                 | 5                   | 1.8 (0.7–4.6) | 0.24 |
| Age                           |                     |   |
| 12–19                         | 34                  | 1  |
| 20–25                         | 10                  | 0.7 (0.4–1.4) | 0.35 |
| Study year                    |                     |   |
| Pre-2005                      | 16                  | 1  |
| 2005 onwards                  | 22                  | 2.4 (1.3–4.4) | <0.01 |
| Adherence measure             |                     |   |
| Self-report                   | 13                  | 0.9 (0.5–1.7) | 0.74 |
| Pill count                    | 1                   | 1.9 (0.3–13.4) | 0.50 |
| Adherence thresholds          |                     |   |
| ≥95%                          | 4                   | 1.7 (0.7–3.7) | 0.21 |
| ≥90%                          | 8                   | 0.9 (0.3–2.5) | 0.84 |
| ≥85%                          | 2                   | 2.6 (0.7–9.4) | 0.13 |

CI, confidence interval; OR, odds ratio.

generation, prevention of mother-to-child-transmission through ART and adherence is critical and AYA-focused appropriate care needs to be reflected in ART delivery and retention programmes.

Our study found that studies that were conducted from 2005 onwards showed higher adherence rate (74%) than studies conducted before 2005 (59%). This is consistent with the fact that in earlier studies, the participants would have had more complicated treatment regimes, higher pill burden and experienced greater toxicity from ART and thus are more likely to have been nonadherent to treatment.

The strengths of this systematic review include explicit eligibility criteria, conduct of a comprehensive search and the usage of random-effects model to pool proportions in keeping with the large heterogeneity. The main limitation is in the quality of the studies. Accurate measurement of adherence has been a challenge to researchers and there is little consistency in adherence classification [87]. Patient recall and pill counts have inherent biases in their measurement [88] such as self-enhancement bias and recall bias, in addition how representative individuals who enrol into adherence studies are of the general populations from which they are drawn in unknown. Furthermore, as studies included were observational studies, some heterogeneity may have been introduced to our study due the lack of standardisation and variations in measuring adherence despite no significant differences between the measures of adherence and the thresholds for adherence were shown in the meta-regression (Table 1). With such high levels of heterogeneity in this study, the results should be interpreted with caution.

Due to the paucity of longitudinal studies, our study only looked at the cross-sectional adherence data, meaning that we were unable to explore the sustainability and dynamics of adherence. Also, the heterogeneity of the information offered by individual studies meant that we were unable to examine the effect of adherence patterns, missed doses and treatment interruptions despite the possibility of these factors having a big impact on the treatment outcome such as immunological recovery and viral resistance to ART and these events tend to occur more frequently amongst AYA [89]. Furthermore, due to the nature of the studies, as with all meta-analyses of published data, we are not able to include data from AYA who, choose not to initiate medication despite eligibility, became lost to follow up or chose not to enrol into a study, or those deemed inappropriate for treatment by their physicians. Information on numerous contributing factors such as incentives and counselling as well as broader contextual factors such as political or socio-demographic status were not available in many studies that may have confounded the adherence level. However, although assessing the impact of all of the possible factors would be informative, it does not change the finding that nearly half of all HIV positive AYA population have suboptimal adherence rates that risks the development of drug resistance, disease progression and transmission to others.

The literature search did not yield studies from Australasia and only three studies from Asia. Moreover, countries such as Brazil, South Africa and United States were overrepresented meaning that these results may reflect adherence rates overall. Finally, there is a possibility that this review has missed articles (unpublished) despite extensive searching, and the restriction to English language may have excluded key data.

Our findings have important implications. Although we were unable to take into account all the possible factors such as drug regimens and adherence dynamics that may affect the overall adherence, we have shown that almost 40% of adolescents with HIV who are eligible for and have started ART are nonadherent to treatment and this level of nonadherence requires action. These data are from a period before recent changes to national guidelines and WHO recommendations that expand eligibility and drug resistance, disease progression and transmission to others.

We assume that the poor reported adherence is highly contextual and multifactorial, but on an individual level, healthcare and public health providers need to proactively engage with AYA to enhance adherence to ART for this vulnerable group. On a policy level, in areas where AYA ART adherence is lower than that of adults (South America and Europe as shown by this study), programmes with better understanding of culturally specific barriers to HIV medication targeting this age group may have the largest potential impact on future health and incidence of HIV. However, in Africa and Asia, where adherence levels in adolescents are relatively high, the exclusion of
high-risk youth from ART may risk preventing potentially adherent patients from lifesaving treatment [34], and although increasing the scale-up of ART coverage in Africa may be beneficial to all, it is critical to enhance access to AYA.

Provision of successful HIV care requires a test and treatment cascade with a potential for drop off at many levels [89,90] and linkage for re-engagement must be offered at every step [91] in order to retest those at risk, and support sustained adherence and retention. Although this analysis focuses only on the latter part of the cascade and only at a single time-point, it has shed light on key gaps in services that could better support AYA living with HIV. In particular, the wide discrepancy in reported adherence between HIV-positive AYA the different continents requires urgent action, especially in resourced settings wherein the delivery of services needs to be appropriately focussed.

Acknowledgements

Funding for this research included the Wellcome Trust (H.W., 090285/Z/09/Z) and the Imperial College NIHR Biomedical Research Centre (S.F.). S.M.G. was funded by a Medical Research Council Population Health Science Fellowship. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Conflicts of interest

There are no conflicts of interest.

References

1. UNICEF. Opportunity in crisis. New York: UNICEF; June 2011.
2. Reinsor S, Mimiaga MJ, Skeer MM, Perkovich MB, Johnson MCV, Satren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Topics in HIV Medicine: a publication of the International AIDS Society, USA 2009; 17:14.
3. Machado JKC, Sant’Anna MJC, Coates V, Almeida FJ, Berezin EN, Omar HA. Brazilian adolescents infected by HIV: epidemiologic characteristics and adherence to treatment. Sci World J 2009; 9:1273–1285.
4. Napierala Mavedzenge SM, Doyle AM, Ross DA. HIV prevention in young people in sub-Saharan Africa: a systematic review. J Adolesc Health 2011; 49:568–586.
5. UNAIDS, Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS 2012. Available at: http://www.unaids.org/en/pub/2012/3208620855/3208620855.pdf [accessed 19 May 2014].
6. Division of HIV/AIDS Prevention NCHHA, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention, Centers for Disease Control and Prevention. HIV among youth. Centers for Disease Control and Prevention; 2013 [cited 03 September 2013]; http://www.cdc.gov/hiv/risk/age/youth/ [accessed 3 September 2013].
7. Bangsgard DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939–941.
8. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21–30.
9. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31:S103–S106.
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505.
11. Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, Spector SA, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retr ovi ruses 2007; 23:1208–1214.
12. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M, Adolescent Medicine HIV/ARN. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2003; 15:27–40.
13. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, Phanthaphak P. Health risk behaviors among HIV-infected youth in Bangkok, Thailand. J Adolesc Health 2007; 40:358.
14. Charles M, Noel F, Leger P, Sereve P, Riviere C, Beaunharnais CA, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008; 86:970–977.
15. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus - infected adolescents. Arch Pediatr Adolesc Med 2003; 157:249–255.
16. Rycavcage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr 2011; 58:193–197.
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264–269.
18. Tebbi C. Treatment compliance in childhood and adolescence. Cancer 1993; 71 (S10):3441–3449.
19. Litt I, Cuskey W. Compliance with medical regimens during adolescence. Pediatr Clin N Am 1980; 27:3.
20. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135–1141.
21. Chesney MA. Adherence to HAART regimens. AIDS Patient Care STDs 2003; 17:169–177.
22. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylá JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105.
23. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404–413.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
25. StaataCorp. inventor; Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
26. Van Der Linden D, Lapointe N, Ransy DG, Motorina A, Soudéyns H, Lamarre V. Portrait of antiretroviral drug resistance in HIV-infected adolescents prior to their transfer to adult care: an exploratory study. Can J Infect Dis Med Microbiol 2011; 22:138.
27. Eisen S, Barkley L, Schepers C, Gurney K, McEnroe M, Shingadia D, et al. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med 2009; 10:45.
28. Egallib A, Samarawickrama A, Roedling S, Tariq S, Draeger E, Hegazi A, et al. Pregnancies in HIV-infected adolescents: a multicentre descriptive study. J Med HIV Med 2009; 10:4.
29. Ellis J, Norrish G, Elgalib A. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med 2009; 10:45.
30. Egallib A, Samarawickrama A, Roedling S, Tariq S, Draeger E, Hegazi A, et al. Pregnancies in HIV-infected adolescents: a multicentre descriptive study. J Med HIV Med 2009; 10:4.
31. Ellis J, Norrish G, Elgalib A. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med 2009; 10:45.
32. Egallib A, Samarawickrama A, Roedling S, Tariq S, Draeger E, Hegazi A, et al. Pregnancies in HIV-infected adolescents: a multicentre descriptive study. J Med HIV Med 2009; 10:4.
33. Ellis J, Norrish G, Elgalib A. Impact of transition to adult services on clinic attendance and virological control in HIV-infected adolescents. HIV Med 2009; 10:45.
34. Egallib A, Samarawickrama A, Roedling S, Tariq S, Draeger E, Hegazi A, et al. Pregnancies in HIV-infected adolescents: a multicentre descriptive study. J Med HIV Med 2009; 10:4.
Meta-analysis adherence to antiretroviral therapy in adolescents Kim et al. 1955

32. Catin, S. Response to combination antiretroviral therapy: a variation age. AIDS 2008; 22:1463–1473.
33. Evans D, Menezes C, Mahomed K, Macdonald, Untiedt S, Levin L, et al. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa. AIDS Res Hum Retroviruses 2013; 29:892–900.
34. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 2009; 45:123–131.
35. Buchanan AL, Montepiedra G, Sirois PA, Kammerer B, Garvie PA, Storm DS, et al. Barriers to medication adherence in HIV-infected children and youth based on self-and caregiver report. Pediatrics 2011; 129:e244–e321.
36. Calabrese SK, Martin S, Wolters PL, Toledo-Tamula MA, Brennan TL, Wood LV. Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care 2012; 24:1092–1096.
37. Chandwani S, Koenig LJ, Sill AM, Abramowitz S, Conner LC, Angulo L. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health 2012; 51:242–251.
38. Comulada WS, Swendeman DT, Rotheram-Borus MJ,Mattes KM, Weiss RE. Use of HAART among young people living with HIV. Ann J Behav Med 2003; 27:399.
39. Flynn PM, Rudy BJ, Douglas SD, Lathey I, Spector SA, Martinezj, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1–infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004; 190:271–279.
40. Garvie PA, Lawford J, Flynn PM, Gaur AH, Belzer M, McSherry GD, et al. Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. J Adolesc Health 2009; 45:124–132.
41. Hosek SG, Harper GW, Domanico R. Predictors of medication adherence among HIV-infected youth. Psychol Health Med 2005; 10:166–172.
42. Marthaler S, Bekington K, Dolezel C, Mellins C. Transmission risk behavior among youth living with perinatally acquired HIV: are nonadherent youth more likely to engage in sexual behavior? J Adolesc Health 2010; 1:529.
43. Martin SC, Wolters PL, Toledo-Tamula MA, Zeichner SL, Hazra R, Civitello L. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Develop Neuropsychol 2006; 30:633–657.
44. Martinez J, Harper G, Carleton RA, Hosek S, Bojan K, Glum G, et al. The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effect of coping and satisfaction with healthcare. AIDS Patient Care STDS 2012; 26:108–115.
45. Mellins CA, Tassiopoulos K, Malee K, Moscicki A-B, Patton D, Smith R, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDS 2011; 25:413–422.
46. Murphy DA, Lam P, Naar-King S, Robert Harris D, Parsons JT, Muenz LR, et al. Health literacy and antiretroviral adherence among HIV-infected adolescents. Patient Educ Counsel 2010; 79:434–439.
47. Park J, Nachman S. The link between religion and HAART adherence in pediatric HIV patients. AIDS Care 2010; 22:556–563.
48. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Adolescent Trials Network for HIVAI. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS 2010; 24:97–104.
49. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Adolescent Trials Network for HIVAI. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS 2009; 23:185–194.
68. Kline MW, Rugina S, Ilie M, Matassa RF, Schweitzer A-M, Calles NR, et al. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. Pediatrics 2007; 119:e1116–e1120.

69. Cruz ML, Cardoso CA, Joao EC, Gomes JM, Abreu TF, Oliveira RH, et al. Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIV-exposed infants. AIDS 2010; 24:2727–2732.

70. de Matos VTC, de Oliveira ALL, de Souza AS, Dal Fabbro MMF. Characteristics of HIV-positive patients infected by vertical transmission, Campo Grande, MS, Brazil, 1993–2009. Sex Trans Infect 2012; 88:525–527.

71. Filho LFR, Nogueira SA, Machado ES, Abreu TF, de Oliveira RH, Evangelista L, et al. Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil, Int J STD AIDS 2008; 19:685–688.

72. Santarem Ernesto A, Muller Banzato Pinto de Lemos R, Huehara ML, Moreno Morcillo A, Dos Santos Vilela MM, Nolasco da Silva MT. Usefulness of pharmacy dispensing records in the evaluation of adherence to antiretroviral therapy in Brazilian children and adolescents. Braz J Infect Dis 2012; 16:315–320.

73. Souza E, Santos N, Valentini S, Silva G, Falbo A. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure. Trop Pediatrics 2010; 56:421–426.

74. Mills EJ, Nachega JB, Buchan I, Birnkis J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America. JAMA 2006; 296:679–680.

75. Paredes R, Mocroft A, Kirk O, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160:1123.

76. Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS 2004; 18:S15–S20.

77. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB, et al. Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 2006; 43:S119–S122.

78. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndr 2009; 51:65–71.

79. Ryscavage PA, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr 2011; 58:193–197.

80. Bank W. Health expenditure, total (% of GDP), 2013 [cited 02 May 2013]. http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS.

81. Prevention CDCa. HIV in the United States: at a glance. 2013 [cited 02 May 2013]. http://www.cdc.gov/hiv/statistics/basics/ataglance.html#ref1 [accessed 2 May 2013].

82. Ayres JD, Paiva V, França Jr, Gravato N, Lacerda R, Della Negra M, et al. Vulnerability, human rights, and comprehensive healthcare needs of young people living with HIV/AIDS. Am J Public Health 2006;96.

83. Prevention CDCa. HIV among black/African American gay, bisexual, and other men who have sex with men, 2013 [cited 17 June 2013]. http://www.cdc.gov/hiv/risk/racialethnic/bmsmfacts/index.html [accessed 17 June 2013].

84. Millet GA, Peterson JL, Flores SA, Hart TA, Jeffrey WL, Wilson PA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet 2012; 380:341–348.

85. Health Protection Agency. HIV in the United Kingdom: 2013 Report. London: Health Protection Services, Colindale. November 2012.

86. Surveys D. Many are mothers at 18 [cited 07 May 2013]. http://www.unicef.org/pon95/fami0009.html [accessed 7 May 2013].

87. Bosworth HB, Oddone EZ, Weinberger M. Patient treatment adherence, 1st ed. Mahwah, N.J.: Lawrence Erlbaum Associates, Publishers; 2006.

88. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968–977.

89. Kranzer K, Govindasamy D, Ford N, Johnston V, Law SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc 2012; 15:17383.

90. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793–800.

91. WHO. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO Library Cataloguing-in-Publication Data; 2013.